This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Background and Date of Approval

The Brentuximab vedotin is medically approved for the treatment of Hodgkin lymphoma, cutaneous T-cell lymphoma and systemic Anaplastic Large Cell Lymphoma.

Mechanism of Action of undefined

Brentuximab vedotin consists of an antibody targeting CD30, a protein found on the surface of cancer cells, and a chemotherapy drug attached to the antibody. The antibody delivers the chemotherapy directly to the cancer cells, minimizing damage to healthy cells.

Uses of undefined

Brentuximab vedotin is used to treat various cancers, including classical Hodgkin lymphoma (both newly diagnosed and relapsed), systemic anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, cutaneous T-cell lymphoma, and CD30-expressing mycosis fungoides, all in combination with other therapies.

undefined Drug administaration and Dosage available

Brentuximab vedotin can be administered only as an intravenous injection into a vein by your physician in a hospital setting. Your physician will decide the correct dosage and duration based on age, body weight, and disease condition.

Warnings, Precautions and Side Effects of undefined

Warnings

Brentuximab vedotin could develop a serious brain infection called progressive multifocal leukoencephalopathy (PML), leading to disability or death. Your blood cell counts might drop, increasing your risk of infections, bleeding, or bruising. Your doctor will monitor your blood regularly. You could experience tingling, numbness, or burning pain in your hands or feet.

Precautions

Watch for new or worsening problems with speech, thought, vision, or muscle movement after taking Brentuximab vedotin, and tell your doctor immediately. Avoid activities that could increase your risk of getting sick, such as being around people with infections. Wear comfortable shoes and avoid activities that put pressure on your nerves. Report any bleeding or bruising, even minor ones.

Side Effects

Brentuximab vedotin can cause serious side effects, including low blood cell counts, which can increase your risk of infection, bleeding, or bruising; tingling, numbness, or burning pain in your hands or feet; lung problems like cough, shortness of breath, or wheezing; high blood sugar; allergic reactions including rash, hives, swelling of the face, throat, or tongue, difficulty breathing; and serious skin reactions.

Word Of Advice

During the course of treatment with Brentuximab vedotin and for a specified period afterward (up to 6 months following the last dose), men are advised not to father a child. This precaution is taken to minimize any serious risks to the unborn child that may arise from exposure to the medication.

Frequently Asked Question

References

  1. Takeda Pharma A/S, Electronic Medicines Compendium (EMC), [Revised on June 2022] [Accessed on 11 August 2023], https://www.medicines.org.uk/emc/files/pil.2859.pdf
  2. Adcetris 50mg injection. Macmillan Cancer Support, [Revised on 1 July 2022], [Accessed on 11 August 2023], www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/brentuximab
  3. Adcetris, INN- Adcetris 50mg injection. [Revised on 10 Jan 2023], [Accessed on 11 August 2023], www.ema.europa.eu/en/documents/product-information/www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf
  4. Seattle Genetics, Inc. US Food & Drug Administration. [Revised Nov 2014], [Accessed on 11 August 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/125388_s056s078lbl.pdf

Disclaimer

The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.